10284 Federal Register / Vol. 62, No. 44 / Thursday, March 6, 1997 / Notices

this policy is contained in the Federal

Register, Vol. 60, No. 179, Friday,

September 15, 1995, pages 47947–

47951.

Application Submission and Deadline

A. Pre-Application Letter of Intent

Although not a prerequisite of

application, a non-binding letter of

intent to apply is requested from

potential applicants. The letter should

be submitted to the Grants Management

Officer whose name is noted in section

B. below. The letter should be

postmarked no later than 30 days prior

to the submission deadline. The letter of

intent should identify the

Announcement Number; name the

proposed project director; and in a

paragraph, describe the scope of the

proposed project. The letter will not

influence review or funding decisions,

but it will enable CDC to plan the

review more efficiently and ensure that

applicants receive timely and relevant

information prior to application

submission.

B. Application Submission

The original and two copies of the

application PHS Form 5161–1 (OMB

Number 0937–0189) should be

submitted to Mr. Ron Van Duyne,

Grants Management Officer, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE., Room 321,

Mailstop E–13, Atlanta, Georgia 30305,

on or before Thursday, May 1, 1997.

1. Deadline: Applications will be

considered as meeting the deadline if

they are either:

(a) Received on or before the deadline

date; or

(b) Sent on or before the deadline date

and received in time for submission to

the objective review group. (Applicants

must request a legibly dated U. S. Postal

Service postmark or obtain a legibly

dated receipt from a commercial carrier

or the U. S. Postal Service. Private

metered postmarks will not be

acceptable as proof of timely mailing.)

2. Late Applications: Applications

that do not meet the criteria in 1.(a) or

1.(b). above are considered late

applications. Late applications will not

be considered in the current

competition and will be returned to the

applicant.

Where To Obtain Additional

Information

To receive additional written

information call (404) 332–4561. You

will be asked your name, address, and

telephone number and will need to refer

to Announcement Number 730. You

will receive a complete program

description, information on application

procedures, and application forms. In

addition, this announcement is also

available through the CDC Home Page

on the Internet. The CDC Home Page

address is http://www.cdc.gov.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from Georgia

L. Jang, Grants Management Specialist,

Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention, 255

East Paces Ferry Road, NE., Room 321,

Mailstop E–13, Atlanta, Georgia 30305,

telephone (404) 842–6814. (Internet

address: glj2@cdc.gov).

Programmatic and operational

information may be obtained from

Joseph B. Smith, Office on Disability

and Health, National Center for

Environmental Health, Centers for

Disease Control and Prevention, 4770

Buford Highway, Building 101, Mailstop

F–29, Atlanta, Georgia 30341, telephone

(770) 488–7082. (Internet address:

jos4@cdc.gov). Epidemiologic and

surveillance-related technical assistance

is available from Donald J. Lollar, Ed.D.

at the same address, telephone (770)

488–7094. (Internet address:

dcl5@.cdc.gov).

An attachment to this Announcement

provides definitions concerning the

conceptional model of disability,

secondary conditions; and includes a

list and description of major State

capacity activities (included in the

application kit and also appended to

this Announcement available through

the CDC Home Page on the Internet

<http://www.cdc.gov>).

Potential applicants may obtain a

copy of ‘‘Healthy People 2000’’ (Full

Report; Stock number 017–001–00474–

0) or ‘‘Healthy People 2000’’ (Summary

Report; Stock number 017–001–00473–

1) through the Superintendent of

Documents, Government Printing

Office, Washington, DC 20402–9325,

telephone (202) 512–1800.

Dated: February 28, 1997.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–5515 Filed 3–5–97; 8:45 am]

BILLING CODE 4163–18–P

Administration for Children and

Families

Agency Record/keeping/Reporting

Requirements Under Emergency

Review by the Office of Management

and Budget (OMB)

Title: Community-Based Family

Resource and Support Grants.

OMB No.: New Collection.

Description: The Program Instruction,

prepared in response to the enactment

of the Community-Based Family

Resource and Support Grants (CBFRS),

as set forth in Title II of Pub. L. 104–

235, Child Abuse Prevention and

Treatment Act Amendments of 1996,

provides direction to the States and

Territories to accomplish the purposes

of (1) supporting State efforts to

develop, operate, expand and enhance a

network of community-based,

prevention-focused, family resource and

support programs that coordinate

resources among existing human service

organizations within the State; and (2)

fostering an understanding,

appreciation, and knowledge of diverse

populations in order to be effective in

preventing and treating child abuse and

neglect. This Program Instruction

contains information collection

requirements that are found in Pub. L.

104–235 at Sections 202(1)(A); 202(b);

203(b)(1)(B); 205; and pursuant to

receiving a grant award. The

information submitted will be used by

the agency to ensure compliance with

the statute, complete the calculation of

the grant award entitlement, and

provide training and technical

assistance to the grantee.

Respondents: State, Local or Tribal

Govt.

ANNUAL BURDEN ESTIMATES

Instrument Number of

respondents

Number of

responses

per respondent

Average burden hours

per response

Total burden

hours

Application ................................................................................................................ 57 1 40 2,280

Annual report ............................................................................................................ 57 1 40 1,368
Federal Register / Vol. 62, No. 44 / Thursday, March 6, 1997 / Notices 10285

ANNUAL BURDEN ESTIMATES—Continued

Instrument Number of

respondents

Number of

responses

per respondent

Average burden hours

per response

Total burden

hours

Estimated total annual burden hours: ............................................................... ...................... ...................... ...................... 3,648

Additional Information: ACF is

requesting that OMB grant a 180 day

approval for this information collection

under procedures for emergency

processing by March 21, 1997. A copy

of this information collection, with

applicable supporting documentation,

may be obtained by calling the

Administration for Children and

Families, Reports Clearance Officer,

Larry Guerrero at (202) 401–6465.

Comments and questions about the

information collection described above

should be directed to the Office of

Information and Regulatory Affairs,

ATTN: OMB Desk Officer for ACF,

Office of Management and Budget,

Paperwork Reduction Project, 725 17th

Street N.W., Washington, D.C. 20503,

(202) 395–7316.

Dated: February 28, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–5451 Filed 3–5–97; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

[Docket No. 97G–0063]

Cerestar Holding Co. B.V., Mitsubishi

Chemical Corp., and Nikken Chemicals

Co., Ltd.; Filing of Petition for

Affirmation of GRAS Status

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Cerestar Holding Co. B.V.,

Mitsubishi Chemical Corp., and Nikken

Chemicals Co., Ltd., have filed a

petition (GRASP 7G0422) proposing to

affirm that the use of erythritol is

generally recognized as safe (GRAS) as

an ingredient in human food.

DATES: Written comments by May 20,

1997.

ADDRESSES: Submit written comments

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, 12420 Parklawn Dr.,

rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:

Rosalie M. Angeles, Center for Food

Safety and Applied Nutrition (HFS–

205), Food and Drug Administration,

200 C St. SW., Washington, DC 20204,

202–418–3107.

SUPPLEMENTARY INFORMATION: Under the

Federal Food, Drug, and Cosmetic Act

(secs. 201(s) and 409(b)(5) (21 U.S.C.

321(s) and 348(b)(5)) and the regulations

for affirmation of GRAS status in

§ 170.35 (21 CFR 170.35), notice is given

that Cerestar Holding Co. B.V.,

Mitsubishi Chemical Corp., and Nikken

Chemicals Co., Ltd., c/o Hyman, Phelps

& McNamara, 700 13th St. NW., suite

1200, Washington, DC 20005, have filed

a petition (GRASP 7G0422) proposing

that erythritol be affirmed as GRAS for

use as an ingredient in human food.

The petition has been placed on

display at the Dockets Management

Branch (address above).

Any petition that meets the

requirements outlined in §§ 170.30 (21

CFR 170.30) and 170.35 is filed by the

agency. There is no prefiling review of

the adequacy of data to support a GRAS

conclusion. Thus, the filing of a petition

for GRAS affirmation should not be

interpreted as a preliminary indication

of suitability for GRAS affirmation.

The potential environmental impact

of this action is being reviewed. If the

agency finds that an environmental

impact statement is not required and

this petition results in a regulation, the

notice of availability of the agency’s

finding of no significant impact and the

evidence supporting that finding will be

published with the regulation in the

Federal Register in accordance with 21

CFR 25.40(c).

Interested persons may, on or before

May 20, 1997, review the petition and

file comments with the Dockets

Management Branch (address above).

Two copies of any comments should be

filed and should be identified with the

docket number found in brackets in the

heading of this document. Comments

should include any available

information that would be helpful in

determining whether the substance is,

or is not, GRAS for the proposed use. In

addition, consistent with the regulations

promulgated under the National

Environmental Policy Act (40 CFR

1501.4(b)), the agency encourages public

participation by review of and comment

on the environmental assessment

submitted with the petition that is the

subject of this notice. A copy of the

petition (including the environmental

assessment) and received comments

may be seen in the Dockets Management

Branch between 9 a.m. and 4 p.m.,

Monday through Friday.

Dated: February 12, 1997.

George H. Pauli,

Acting Director, Office of Premarket

Approval, Center for Food Safety and Applied

Nutrition.

[FR Doc. 97–5454 Filed 3–5–97; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

[Document Identifier: HCFA–3427]

Agency Information Collection

Activities: Submission for OMB

Review; Comment Request

AGENCY: Health Care Financing

Administration.

In compliance with the Paperwork

Reduction Act of 1995 (44 U.S.C. 3501

et seq.), the Health Care Financing

Administration (HCFA), Department of

Health and Human Services, has

submitted to the Office of Management

and Budget (OMB) the following

proposals for the collection of

information. Interested persons are

invited to send comments regarding the

burden estimate or any other aspect of

this collection of information, including

any of the following subjects: (1) the

necessity and utility of the proposed

information collection for the proper

performance of the agency’s functions;

(2) the accuracy of the estimated

burden; (3) ways to enhance the quality,

utility, and clarity of the information to

be collected; and (4) the use of

automated collection techniques or

other forms of information technology to

minimize the information collection

burden.

Type of Information Collection

Request: Reinstatement, with change, of

previously approved collection for

which approval has expired; Title of

Information Collection: End Stage Renal

Disease (ESRD) Application and Survey

and Certification Report Form; Form

No.: HCFA–3427; Use: This form is a

facility identification and screening

measurement tool used to initiate the

certification and recertification of ESRD